Tvardi Therapeutics (TVRD) Change in Accured Expenses (2013 - 2026)

Tvardi Therapeutics has reported Change in Accured Expenses for 14 years, with the latest figure at $212000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 108.02% year-over-year to $212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 71.13% YoY) and the FY2025 annual result came in at $919000.0, down 83.49% from the prior year.
• Change in Accured Expenses declined to $212000.0 in Q1 2026 per TVRD's latest filing, from $787000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $12.7 million in Q2 2024 and troughed at -$10.2 million in Q1 2024.
• A 5-year average of $978250.0 and a median of $713500.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses surged 2089.34% in 2022, then tumbled 1087.19% in 2023.
• Over 5 years, Change in Accured Expenses stood at -$4.8 million in 2022, then soared by 167.8% to $3.2 million in 2023, then soared by 42.34% to $4.6 million in 2024, then tumbled by 82.92% to $787000.0 in 2025, then sank by 73.06% to $212000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $212000.0, $787000.0, and $2.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.